Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 4—August 2001
West Nile Virus
West Nile Virus

Rapid Determination of HLA B*07 Ligands from the West Nile Virus NY99 Genome

Anne S. De Groot*†Comments to Author , Caitlin Saint-Aubin*, Andrew Bosma*, Hakima Sbai*, James Rayner†, and William Martin†
Author affiliations: *Brown University, Providence, Rhode Island, USA; †EpiVax, Inc., Providence, Rhode Island, USA

Main Article

Table 4

Projected cost of HLA-B7 epitope mapping for the West Nile virus genome

EpiMatrix Overlapping (OL)a (10 AA long OL by 5 AA) Complete OL set (decamers overlapping by 9)
Peptides 20 685 3,424
Peptide synthesis $5,000 $171,250 $856,000
Time (days) 28 959 4,794
Technician/reagent cost $2,608 $89,332 $446,527
cost (synthesis + assay) 12 ligandsb $634 $21,715 $108,544
cost (synthesis + assay) 72 ligandsc $617 $3,619 $18,091

aThe standard overlapping approach, constructing a set of 10 amino-acid long peptides overlapping by 5 amino acids (10/5 OL set) would require the synthesis of 685 decamer peptides, approximately 30 times the number synthesized and tested by the EpiMatrix approach. The "discovery" cost per ligand was calculated by dividing the total cost of synthesis and screening for each of the approaches by the number of ligands expected to be discovered (12 ligands, a low estimate, and 72 ligands, a high estimate).
bBased on the assumption that only 12 ligands will be found
cBased on the assumption that as many as 72 ligands may be found. In that case, 95 peptides would be synthesized for EpiMatrix, 685 for OL (10 by 5), and 3,434 for the exhaustive approach.

Main Article

Page created: April 27, 2012
Page updated: April 27, 2012
Page reviewed: April 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.